Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Cancellation

<< Previous

Bullboard Posts

Next >>

Comment by Chianchinon Dec 09, 2022 4:45pm

188 Views

Post# 35162758

RE:RE:RE:RE:RE:Cancellation

Losing money bs mugsy is correct that GUD did the PP at the high. The results of that, investor who bought the PP had faith in GUD MNGT. Eight years later that faith has rewarded them with a 50% capital loss plus 35% opportunity cost of the cash. Is this a company that builds inveastor trust?

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale